Opinion

Video

First-Line Therapy for Chronic GvHD

Author(s):

Hana Safah, MDCorey S. Cutler, MD, MPH, FRCPC

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Related Videos
Paolo Tarantino, MD
Shella Saint Fleur-Lominy, MD, PhD
Manali Kamdar, MD
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Video 8 - 2 KOLs featured in , "Q&A: Final Questions on Glioblastoma and Neuroimaging"
Video 7 - 2 KOLs featured in, "Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment "
Sattva S. Neelapu, MD
Joaquim Bellmunt, MD, PhD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Related Content
The FDA has approved blinatumomab (Blincyto) for the treatment of adult and pediatric patients aged 1 month or older who have CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia in the consolidation phase, irrespective of measurable residual disease status.
June 14th 2024

FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase

Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School
March 28th 2024

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Josep-Maria Ribera MD, PhD
June 14th 2024

Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Haifa Kathrin Al-Ali, MD
June 14th 2024

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

Ibrahim T. Aldoss, MD
June 14th 2024

CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL